Last week, a team of Israeli researchers from the pharmaceutical laboratory announced Accelerated Evolution Biotechnologies Ltd. (AEBi) the development of a drug that could kill cancer cells. The company has already completed the first experiment on mice and several studies & # 39; in vitro & # 39; and is about to begin clinical trials that would be conducted for several years and, according to the researchers, would allow the use of the treatment in specific cases.
Chairman of AEBi, Dan Aridor, confirmed that the company could offer with its innovative treatment "a complete cure" for cancer next year. The news was received with skepticism in the scientific community, and the effectiveness of the method was questioned because of the limited information available on the study, which has not been published in a recognized scientific journal, and the fact that the success of experiments in mice It does not show the effect of the same method in humans.
I also read: The cure will be ready in a year
What is the Israeli treatment?
It's a kind of antibiotic, the so-called multipurpose toxin MuTaTo (for its acronym in English), a combination of peptides that, together with a powerful peptide toxin, specifically attacks cancer cells, eliminating the possibility of the disease coming back.
The MuTaTo treatment is based on the technology of the phage display group which includes encoding DNA for a protein, such as an antibody in a bacteriophage, a virus that infects bacteria. Phage display was developed by American researcher George Smith, who received the Nobel Prize in Chemistry in 2018 for his method of using a bacteriophage to develop new proteins.
As explained last Monday, Ilan Morad, founder and CEO of AEBi, used in MuTaTo at least three peptides against the same structure and by attacking three receptors at the same time instead of one, eliminating the possibility of mutations of cancer cells that would modify all targeted recipients almost: "Even cancer cannot mutate three receptors at the same time", pick up Jerusalem Post.
Morad also excludes the possibility of activating the detoxification mechanisms that occur when cancer cells suffer from the effects of drugs and pump them out or alter them in such a way that they stop working. The researcher claims that if the toxin is strong, there is a high probability of killing the cancer cell before the tax begins, which requires some time.
How will MuTaTo distinguish itself from other cancer treatments?
"We did the same as the others, trying to discover new individual peptides for specific cancers"Morad confessed and remembered when his company had just arrived. Shortly thereafter, the researchers decided to discover why other drugs and cancer treatments do not work and the disease returns over time and concluded that most of the existing drugs attack a specific cancer cell target or inside and they cannot prevent mutations that make them ineffective.
For its part, MuTaTu, according to Israeli scientists, can even overcome the shields created by certain cancerous tumors that do not allow access to large molecules such as antibodies. Morad describes that the peptide moieties of the multi-objective toxin are very small, 12 amino acids in length and lack a rigid structure that allows them to overcome this barrier where larger molecules cannot enter.
In AEBi, they believe that a treatment with MuTaTo would kill cancer cells within weeks – as opposed to treating AIDS, when patients need to take certain drugs throughout their lives – and the possible side effects will be drastically reduced, as the technology only targets cancer cells and not healthy.